You searched for "PCa"

170 results found

LoFric Elle Wins ‘Look Good, Feel Good’ Award

Wellspect’s revolutionary new female catheter has added another award to its list of accolades. The 'Look Good, Feel Good' award, which is a joint initiative of Bladder and Bowel UK and the...

PSA screening in limbo: how low should we go?

One may wonder how the management of prostate cancer could have evolved differently if it had followed a path similar to breast cancer. In breast cancer, early detection in the 1970s relied heavily on imaging because no reliable circulating biomarker...

Consensus statements on PSA testing in asymptomatic men in the UK

In January 2016, the UK National Screening Committee once again recommended against a systematic population screening programme for prostate cancer due to the, as yet, insufficient evidence that the benefits of screening would outweigh the harm to the population as...

Simple spit test could finally turn the tide on prostate cancer

Saliva test which analyses genetic variants in DNA is better than the PSA blood test at assessing prostate cancer risk for some men, and doesn’t require a visit to the GP. The test gave fewer false positive results and picked...

Prostate cancer now England’s most common cancer

Prostate cancer cases overtook those of breast cancer by thousands in both 2022 and 2023, according to Prostate Cancer UK analysis of NHS data. Huge increase shows that more men than ever before are learning about their risk and taking...

Urolithiasis 1 – ureteric colic

- Click for Part 2 on this topic - Case scenario A 45-year-old male presents to Accident & Emergency with two days of intermittent, severe, left-sided loin to groin pain and multiple episodes of vomiting. He undergoes imaging as part...

MRI screening for prostate cancer: a step towards a ‘prostagram’

The UK National Screening Committee has been calling for further research into alternative screening tests for prostate cancer. The committee decided against prostate cancer screening using prostate specific antigen (PSA) testing on the basis that “PSA is still a poor...

The EP2 receptor – a novel target for prostate cancer?

This basic science paper sets out to evaluate the effects that celecoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor, have on prostate cancer cell lines and evaluated the mechanisms behind these effects. COX-2 induces the production of prostaglandins, which promote cell proliferation...

Long-term oncologic outcomes of salvage cryoablation for rrPC

Of patients undergoing radiotherapy (RT) for prostate cancer (PC), at least 15-20% will experience recurrence. Although salvage prostatectomy achieves durable oncological outcomes at 10 years, it is associated with significantly high morbidity. Thus, the majority of men with radio-recurrent prostate...

Prostate Cancer UK: PSA Consensus Conference 2024

During the conference, you'll get up-to-date information on the latest consensus regarding the PSA blood test. You'll also be able to discuss the diagnostic process for secondary care and learn how to proactively manage conversations about prostate health with patients who are at higher risk. You’ll have plenty of opportunities to ask questions, interact with peers, and apply what you learn through engaging case studies. 9am – 12.30pm

Prostate Cancer Diagnosis – PSA, Biopsy and Beyond

The danger of many of the texts which deal with this rapidly changing field is that by the time the texts are published they are out of date. This book however remains fresh, in part because it acknowledges that there...